CN104583393A - 病毒样颗粒的纯化 - Google Patents

病毒样颗粒的纯化 Download PDF

Info

Publication number
CN104583393A
CN104583393A CN201380043618.XA CN201380043618A CN104583393A CN 104583393 A CN104583393 A CN 104583393A CN 201380043618 A CN201380043618 A CN 201380043618A CN 104583393 A CN104583393 A CN 104583393A
Authority
CN
China
Prior art keywords
vlps
solution
vlp
norovirus
chromatography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380043618.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Priority to CN202111173161.7A priority Critical patent/CN114085273B/zh
Publication of CN104583393A publication Critical patent/CN104583393A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380043618.XA 2012-06-22 2013-06-24 病毒样颗粒的纯化 Pending CN104583393A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111173161.7A CN114085273B (zh) 2012-06-22 2013-06-24 病毒样颗粒的纯化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261663218P 2012-06-22 2012-06-22
US61/663,218 2012-06-22
US201361794086P 2013-03-15 2013-03-15
US61/794,086 2013-03-15
PCT/US2013/047249 WO2013192604A1 (en) 2012-06-22 2013-06-24 Purification of virus like particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111173161.7A Division CN114085273B (zh) 2012-06-22 2013-06-24 病毒样颗粒的纯化

Publications (1)

Publication Number Publication Date
CN104583393A true CN104583393A (zh) 2015-04-29

Family

ID=49769461

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380043618.XA Pending CN104583393A (zh) 2012-06-22 2013-06-24 病毒样颗粒的纯化
CN202111173161.7A Active CN114085273B (zh) 2012-06-22 2013-06-24 病毒样颗粒的纯化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111173161.7A Active CN114085273B (zh) 2012-06-22 2013-06-24 病毒样颗粒的纯化

Country Status (15)

Country Link
US (3) US10167320B2 (enExample)
EP (1) EP2864478B1 (enExample)
JP (1) JP6553509B2 (enExample)
KR (1) KR102110876B1 (enExample)
CN (2) CN104583393A (enExample)
AR (1) AR091538A1 (enExample)
AU (1) AU2013277959B2 (enExample)
CA (1) CA2879815A1 (enExample)
IN (1) IN2015DN00089A (enExample)
JO (1) JOP20130186B1 (enExample)
MX (1) MX366234B (enExample)
SG (2) SG11201408459VA (enExample)
TW (1) TWI647310B (enExample)
UY (1) UY34875A (enExample)
WO (1) WO2013192604A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105339495A (zh) * 2013-07-11 2016-02-17 宝生物工程株式会社 制备无包膜病毒的方法
CN105779399A (zh) * 2016-03-28 2016-07-20 广西壮族自治区林业科学研究院 一种昆虫杆状病毒纯化方法
CN105907729A (zh) * 2015-05-05 2016-08-31 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
CN107034198A (zh) * 2015-07-15 2017-08-11 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CN108430502A (zh) * 2015-08-28 2018-08-21 科学生物技术公司 诺瓦克病毒疫苗
CN108676781A (zh) * 2018-05-18 2018-10-19 山东信得动物疫苗有限公司 一种重组禽流感病毒的工业化纯化方法
CN109689092A (zh) * 2016-09-01 2019-04-26 武田疫苗股份有限公司 用于产生用于疫苗生产的病毒的方法
CN116789773A (zh) * 2022-11-30 2023-09-22 华北制药金坦生物技术股份有限公司 一种胞内表达病毒样颗粒的粗纯方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2601969T3 (en) 2006-09-29 2016-04-18 Takeda Vaccines Inc Norovirus vaccine formulations
KR101576219B1 (ko) 2007-03-14 2015-12-10 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
SG184733A1 (en) 2007-09-18 2012-10-30 Ligocyte Pharmaceuticals Inc Method of conferring a protective immune response to norovirus
DK3299030T3 (da) 2011-07-11 2022-09-05 Takeda Vaccines Inc Parenterale norovirus-vaccineformuleringer
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN106103720A (zh) 2013-10-03 2016-11-09 武田疫苗股份有限公司 自细胞系检测和除去弹状病毒的方法
CN103981084B (zh) * 2014-05-29 2015-11-18 黑龙江省科学院微生物研究所 水中病毒分离提取装置及水中札幌病毒的提取方法
EP3243904A4 (en) * 2015-01-09 2018-06-27 Takara Bio Inc. Method for producing non-enveloped viral particles
JP6893174B2 (ja) * 2015-01-16 2021-06-23 タケダ ワクチン，インコーポレイテッド 粒子に含まれる逆転写酵素活性の検出
GB201614050D0 (en) 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
EP4382183A3 (en) 2017-03-06 2024-08-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
EP3752185A1 (en) 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
CN111848749A (zh) * 2018-05-23 2020-10-30 中国农业科学院兰州兽医研究所 猪细小病毒VLPs抗体检测试剂盒及其制备方法、应用
EP3938378B1 (en) 2019-03-12 2023-08-02 Icon Genetics GmbH Norovirus-like particles with improved stability
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
EP4362975A4 (en) * 2021-06-28 2025-05-14 VST LLC dba Medgene Labs SAPOVIRUS VACCINES
WO2025077800A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Purification of norovirus virus-like particles (vlps)
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150961A1 (en) * 2007-03-14 2010-06-17 Vedvick Thomas S Virus like particle purification
US20120156243A1 (en) * 2006-09-29 2012-06-21 LigoCyte Pharmaceutical Norovirus vaccine formulations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
EP0757717B1 (en) 1994-05-16 2006-05-31 Merck & Co. Inc. Papillomavirus vaccines
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3316325B2 (ja) * 1994-12-20 2002-08-19 富士シリシア化学株式会社 ビール安定化処理用シリカゲル及びその製造方法並びにビールの安定化処理方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69739268D1 (de) 1996-11-08 2009-04-02 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
DE122007000015I2 (de) 1997-09-05 2008-01-24 Medimmune Inc Methode zur in Vitro auseinander- und wiederzusammensetzung von Papillomavirus virusähnlichen Teilchen (vlps)
DE19823814A1 (de) 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
AU760633B2 (en) 1998-08-14 2003-05-22 Merck Sharp & Dohme Corp. Process for purifying human papillomavirus virus-like particles
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US6349843B1 (en) 1999-04-01 2002-02-26 The Vollrath Company Llc Pan removal ramp
KR100771402B1 (ko) 1999-06-22 2007-10-30 국립감염증연구소장이 대표하는 일본국 Ｓｒｓｖ 검출 킷트
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
JP2003066021A (ja) 2001-08-28 2003-03-05 Hiroshi Shionoya 連続分取液体クロマトグラフィー装置とそれを用いる方法
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US8277819B2 (en) 2005-06-16 2012-10-02 Children's Hospital Medical Center Norovirus particle for use as an antiviral or vaccine
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
HUE054868T2 (hu) 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP2027875A1 (en) 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
SG184733A1 (en) 2007-09-18 2012-10-30 Ligocyte Pharmaceuticals Inc Method of conferring a protective immune response to norovirus
EP2235165A1 (en) 2007-12-21 2010-10-06 Cytos Biotechnology AG Process for clarifying cell homogenates
CA2733589C (en) 2008-08-08 2021-07-13 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2010062757A1 (en) 2008-11-03 2010-06-03 Ligocyte Pharmaceuticals, Inc. Improved methods for isolating enveloped virus-based vlps free of infectious agents
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
CA2787666A1 (en) 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
EP2619217B1 (en) 2010-09-20 2016-11-09 Bio-Rad Laboratories, Inc. Dissociation of product-complexed contaminants in chromatography
FI122520B (fi) 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CN102260651A (zh) 2011-06-24 2011-11-30 华中科技大学同济医学院附属协和医院 一种纯化病毒样颗粒蛋白的方法及其应用
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156243A1 (en) * 2006-09-29 2012-06-21 LigoCyte Pharmaceutical Norovirus vaccine formulations
US20100150961A1 (en) * 2007-03-14 2010-06-17 Vedvick Thomas S Virus like particle purification

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GABRIEL I. PARRA，ET AL: "Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations", 《VACCINE》 *
HUAFANG LAI • QIANG CHEN: "Bioprocessing of plant-derived virus-like particlesof Norwalk virus capsid protein under current Good Manufacture Practice regulations", 《PLANT CELL REP》 *
L. HUHTI，ET AL: "A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles", 《ARCH VIROL》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105339495A (zh) * 2013-07-11 2016-02-17 宝生物工程株式会社 制备无包膜病毒的方法
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
CN105907729A (zh) * 2015-05-05 2016-08-31 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
US11116831B2 (en) 2015-07-15 2021-09-14 Changchun Bcht Biotechnology Co. Chimeric norovirus P particle and preparation and use thereof
CN107034198A (zh) * 2015-07-15 2017-08-11 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CN107034198B (zh) * 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CN108430502A (zh) * 2015-08-28 2018-08-21 科学生物技术公司 诺瓦克病毒疫苗
US11596680B2 (en) 2015-08-28 2023-03-07 Resilience Government Services, Inc. Norovirus vaccine
CN105779399A (zh) * 2016-03-28 2016-07-20 广西壮族自治区林业科学研究院 一种昆虫杆状病毒纯化方法
CN109689092A (zh) * 2016-09-01 2019-04-26 武田疫苗股份有限公司 用于产生用于疫苗生产的病毒的方法
CN108676781A (zh) * 2018-05-18 2018-10-19 山东信得动物疫苗有限公司 一种重组禽流感病毒的工业化纯化方法
CN116789773A (zh) * 2022-11-30 2023-09-22 华北制药金坦生物技术股份有限公司 一种胞内表达病毒样颗粒的粗纯方法
CN116789773B (zh) * 2022-11-30 2024-02-20 华北制药金坦生物技术股份有限公司 一种胞内表达病毒样颗粒的粗纯方法

Also Published As

Publication number Publication date
SG11201408459VA (en) 2015-01-29
CN114085273A (zh) 2022-02-25
MX366234B (es) 2019-07-03
JP6553509B2 (ja) 2019-07-31
IN2015DN00089A (enExample) 2015-05-29
US20220213147A1 (en) 2022-07-07
TW201406956A (zh) 2014-02-16
EP2864478B1 (en) 2020-12-09
CA2879815A1 (en) 2013-12-27
UY34875A (es) 2013-12-31
US10167320B2 (en) 2019-01-01
AU2013277959A1 (en) 2015-01-22
KR20150051988A (ko) 2015-05-13
MX2014015842A (es) 2015-09-07
EP2864478A4 (en) 2015-12-02
EP2864478A1 (en) 2015-04-29
SG10201610753YA (en) 2017-02-27
CN114085273B (zh) 2024-07-12
JP2015521628A (ja) 2015-07-30
US11091519B2 (en) 2021-08-17
AR091538A1 (es) 2015-02-11
AU2013277959B2 (en) 2019-05-16
US20140004145A1 (en) 2014-01-02
JOP20130186B1 (ar) 2021-08-17
US12286456B2 (en) 2025-04-29
HK1210210A1 (en) 2016-04-15
US20190169236A1 (en) 2019-06-06
TWI647310B (zh) 2019-01-11
WO2013192604A1 (en) 2013-12-27
KR102110876B1 (ko) 2020-05-14

Similar Documents

Publication Publication Date Title
US12286456B2 (en) Purification of virus like particles
US12227540B2 (en) Saponin purification
CN1145639C (zh) 呼吸道合胞体病毒亚基疫苗制剂
CN105745218B (zh) 去除残留细胞培养杂质
CA2433502A1 (en) Acellular pertussis vaccines and methods of preparation thereof
KR20220141302A (ko) 코로나 바이러스 백신 제제
WO1991000104A1 (en) Production of virus and purification of viral envelope proteins for vaccine use
JP4523164B2 (ja) ワクチン
CN105018435A (zh) 一种病毒样颗粒的纯化方法
JP7317796B2 (ja) 呼吸器疾患を治療するための方法および組成物
CA3142300C (en) SAPONIN PURIFICATION
CN106163553A (zh) 多聚体‑多表位流感多肽的组合物及其产生
CN105612250A (zh) 经处理的滤器
HK1210210B (en) Purification of virus like particles
US20180273909A1 (en) Purification of respiratory syncytial virus
CN117717608B (zh) 一种包含肺炎球菌与流感病毒的联合疫苗、制备方法及其应用
CN106434570A (zh) 一种狂犬病病毒裂解液及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: TAKEDA VACCINES, INC.

Address before: Illinois State

Applicant before: TAKEDA VACCINES, INC.

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20150429

RJ01 Rejection of invention patent application after publication